Indication: Antiemetics. Mainly used for 1. symptomatic treatment of nausea, vomiting, belching, indigestion, stomach distension, hyperacidity and other symptoms caused by various causes; 2. reflux esophagitis, bile reflux gastritis, functional gastric retention, gastroptosis, etc.; 3. delayed emptying of residual stomach, delayed gastric emptying after vagotomy; 4. gastric emptying disorders caused by collagen diseases such as diabetic gastroparesis, uremia, scleroderma, etc.

Indication: Antiemetics. Mainly used for 1. symptomatic treatment of nausea, vomiting, belching, indigestion, stomach distension, hyperacidity and other symptoms caused by various causes; 2. reflux esophagitis, bile reflux gastritis, functional gastric retention, gastroptosis, etc.; 3. delayed emptying of residual stomach, delayed gastric emptying after vagotomy; 4. gastric emptying disorders caused by collagen diseases such as diabetic gastroparesis, uremia, scleroderma, etc.

Indication: Antiemetics. Mainly used for 1. symptomatic treatment of nausea, vomiting, belching, indigestion, stomach distension, hyperacidity and other symptoms caused by various causes; 2. reflux esophagitis, bile reflux gastritis, functional gastric retention, gastroptosis, etc.; 3. delayed emptying of residual stomach, delayed gastric emptying after vagotomy; 4. gastric emptying disorders caused by collagen diseases such as diabetic gastroparesis, uremia, scleroderma, etc.

Indication: Antiemetics. Mainly used for 1. symptomatic treatment of nausea, vomiting, belching, indigestion, stomach distension, hyperacidity and other symptoms caused by various causes; 2. reflux esophagitis, bile reflux gastritis, functional gastric retention, gastroptosis, etc.; 3. delayed emptying of residual stomach, delayed gastric emptying after vagotomy; 4. gastric emptying disorders caused by collagen diseases such as diabetic gastroparesis, uremia, scleroderma, etc.

Indication: Antiemetics. Mainly used for 1. symptomatic treatment of nausea, vomiting, belching, indigestion, stomach distension, hyperacidity and other symptoms caused by various causes; 2. reflux esophagitis, bile reflux gastritis, functional gastric retention, gastroptosis, etc.; 3. delayed emptying of residual stomach, delayed gastric emptying after vagotomy; 4. gastric emptying disorders caused by collagen diseases such as diabetic gastroparesis, uremia, scleroderma, etc.

Indication: Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Limitations of Use Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [ see Use in Specific Populations ( 8. 4 Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 Limitations of Use Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.

Indication: Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Limitations of Use Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [ see Use in Specific Populations ( 8. 4 Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 Limitations of Use Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.

Indication: Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide injection, USP (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection, USP is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection, USP is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide injection, USP may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection, USP may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine.

Indication: Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Limitations of Use Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [ see Use in Specific Populations ( 8. 4 Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 Limitations of Use Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.

Indication: Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Limitations of Use Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [ see Use in Specific Populations ( 8. 4 Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 Limitations of Use Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.